Competition for NDA Approval Begins Before "First-in-Class" Drugs Receive Market Approval

November 5, 2015

On November 3, 2015, Tufts Center for the Study of Drug Development (CSDD) published its November/December Tufts CSDD Impact Report. According to the report, when “first-in-class” drugs receive market approval a number of follow-on products are already well into the regulatory process.

The study analyzed 40 different classes of pharmaceutical products, including both drugs and biologics from 1998 – 2011 and found:

  • 83% of all later-in-class drugs had at least initiated Phase II clinical testing abroad or in the U.S. prior to U.S. marketing approval for the first-in-class drug.
  • All later-in-class drugs had a patent filed somewhere in the world before the first-in-class drug was approved in the United States; 96% had a U.S. patent filed before first-in-class approval.
  • More than half of all later-in-class drugs received a ‘priority rating’ from the FDA.

According to the report, the race for marketing approval among these products is increasingly competitive. Jopseph DiMasi, Ph.D., Director of Economic Analysis & Research Associate Professor at Tufts CSDD, noted that the development of first-in-class drugs oftentimes begins later than that of competitive drugs in the same class.

Study results show by the time first-in-class approval is granted, the “later-in-class” products are in the following stages of development:

1998 – 2011 2005 – 2011
Phase I 66% 90%
Phase II 60% 83%
Phase III 42% 57%

 

Half of all later-in-class products were approved within 2.7 years of first-in-class products that were approved between 1998 and 2011. That same timeframe was reduced to 2.3 years for first-in-class products approved between 2005 and 2011.

DiMasi’s bottom line is that drug development is a “competitive race.” This race occurs “before regulatory success for any drug in the class has been established.”

Are you in the process of developing or obtaining approval for a first-in-class or later-in-class product? Using our proprietary approach, we can help you get through FDA cheaper, faster, and better. To learn more about how we can help you, please contact us.



ANDA FDA

November 5, 2015

How GDUFA II Impacts the Timing and Approval Process for Generic Drug Sponsors

How GDUFA II Impacts the Timing and Approval Process for Generic Drug Sponsors: Facing several regulatory challenges related to the review of abbreviated new drug applications (ANDAs), Congress first...

Read More
Agency Alerts General Regulatory

November 5, 2015

Report: FDA’s Drug Review & Approval Times Reduced Drastically Since 2009

According to an infographic report from the California Life Sciences Association (CLSA), FDA approval times have decreased by nearly 50% since 2009.  The infographic, entitled “Tracking FDA Drug...

Read More
Generic Drugs Agency Alerts

November 5, 2015

2016 was Record-Setting Year for Generic Drug Approvals, Reports FDA

In a recent post on the FDA Voice blog, the Agency reported that its generic drug program hit record highs in 2016.  In the blog post, Kathleen “Cook” Uhl, M.D., Director of FDA’s Office of Generic...

Read More